Asked by: Baroness Maclean of Redditch (Conservative - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government by how much demand for mental health, ADHD and autism services is increasing or decreasing in each of the past five years for people aged (1) under 16, (2) 16-24, (3) 25-34, (4) 35-49, (5) 50-64, and (6) over 65.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
The following table shows the number of people in contact with National Health Service funded secondary mental health, learning disabilities and autism services, in each financial year between 2020/21 and 2024/25:
Age group | 2020/21 | 2021/22 | 2022/23 | 2023/24 | 2024/25 |
Under 16 years old | 593,297 | 776,750 | 869,206 | 915,617 | 986,814 |
16-24 years old | 499,690 | 595,233 | 642,990 | 640,187 | 678,667 |
25-34 years old | 385,511 | 438,756 | 500,668 | 542,170 | 606,461 |
35-49 years old | 424,031 | 466,396 | 525,588 | 581,642 | 661,362 |
50-64 years old | 331,311 | 357,524 | 388,097 | 418,523 | 449,505 |
65 years old and over | 563,811 | 609,373 | 647,310 | 675,575 | 685,797 |
UNKNOWN | 5,593 | 12,663 | 9,005 | 17,112 | 60,684 |
Source: Mental Health Services Data Set (MHSDS)
Notes:
The following table shows the number of people known to be in contact with NHS Talking Therapies in each financial year between 2020/21 and 2024/25:
Age group | 2020/21 | 2021/22 | 2022/23 | 2023/24 | 2024/25 |
|
Under 16 years old | 1,222 | 1,189 | 925 | 886 | 749 |
|
16-24 years old | 360,673 | 424,826 | 398,859 | 370,377 | 350,213 |
|
25-34 years old | 487,273 | 571,094 | 563,973 | 555,142 | 543,044 |
|
35-49 years old | 437,838 | 514,275 | 537,364 | 564,755 | 583,614 |
|
50-64 years old | 265,491 | 311,633 | 332,821 | 358,120 | 366,773 |
|
65 years old and over | 89,446 | 108,885 | 123,740 | 136,297 | 140,262 |
|
Source: Improving Accessing to Psychological Therapies dataset Notes:
| ||||||
Asked by: Lord Kamall (Conservative - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government, what steps they are taking to identify regulatory barriers and evaluate reimbursement policies for brain cancer therapies.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government recognises that there are currently limited treatment options available for people who have been diagnosed with cancerous brain tumours and recognises the significant impact this rare cancer can have on patients, carers, and their families. All new licensed medicines, including medicines for brain cancer, are evaluated by the National Institute for Health and Care Excellence (NICE), which makes recommendations for the National Health Service on whether they represent a clinically and cost effective use of NHS resources. NICE is actively evaluating a number of new medicines for potential use in the treatment of brain cancers.
NICE works closely with companies and the medicines regulator, the Medicines and Healthcare products Regulatory Agency (MHRA), and aims to issue guidance on new medicines as close as possible to the time of licensing. The NHS in England is legally required to fund medicines recommended by NICE and funding from the Cancer Drugs Fund is available for cancer medicines from the point of a draft positive NICE recommendation, bringing forward patient access by up to five months.
The MHRA has several pathways which facilitate rapid assessment of medicines. This includes international collaborations such as Project Orbis and the Access Consortium. The MHRA has also introduced the International Recognition Pathway, which allows the MHRA to take into account the expertise and decision-making of trusted regulatory partners, and the Innovative Licensing and Access Pathway scheme, focussed on getting new and transformative medicines to patients in the UK health system more quickly. Recently, the MHRA also issued new regulations to make it faster and easier for cutting-edge cancer treatments and personalised gene therapies to be made right where patients are treated.
Asked by: Lord Kamall (Conservative - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what plans they have to ringfence funding for brain cancer research.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
Research is crucial in tackling cancer, which is why the Department invests over £1.6 billion per year in research through the National Institute for Health and Care Research (NIHR). Cancer is a major area of NIHR spending at £141.6 million in 2024/25, reflecting its high priority.
Too little is known about how to prevent, diagnose, and manage brain tumours. They remain one of the hardest cancers to treat and a challenging area for research. That is why we are committed to furthering our investment in brain cancer research and have already taken steps to stimulate scientific progress.
In December 2025, the NIHR announced an initial £13.7 million investment in the pioneering Brain Tumour Research Consortium to accelerate research into new brain tumour treatments. Significant further funding is due to be awarded shortly. The world-leading consortium aims to transform outcomes for adults and children and their families who are living with brain tumours, ultimately reducing lives lost to cancer.
The NIHR continues to welcome funding applications for research into any aspect of human health and care, including brain cancer. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to the public and health and care services, value for money, and scientific quality. Welcoming applications on brain cancer to all NIHR programmes enables maximum flexibility both in terms of the amount of research funding a particular area can be awarded, and the type of research which can be funded.
Asked by: Andrew Snowden (Conservative - Fylde)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what discussions his Department has had with technology companies used by his Department on the automated processing of emails that contain personal health information.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department does not process personal health information. This type of information is handled by NHS England and other authorised health bodies.
We work closely with NHS England to ensure that any technology used across the health system meets the legal and ethical standards required for safeguarding personal health data. This includes data protection, information governance, and the safeguards required for handling health data. These checks ensure that any system we bring into use aligns with the rules that protect people’s privacy.
When personal data is processed as part of specific programmes, it is handled by approved delivery partners under strict governance arrangements. These partners act only on behalf of the Department and in line with data protection law and contractual controls.
Asked by: Lord Bradley (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what action they are taking to extend independent prescribing responsibilities to occupational therapists.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
We support the expansion of non-medical professional groups being able to use legal mechanisms to prescribe, supply, and administer medicines to patients where it is safe to do so. There is a robust process in place for making such changes to ensure they are safe and beneficial for patients.
We are considering requests for the extension of existing medicines responsibilities and recently concluded a consultation on proposals to extend the medicines responsibilities of four professions. Further information can be found on the GOV.UK website.
Asked by: Lord Bird (Crossbench - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what assessment they have made of the impact of digital exclusion on access to healthcare services, including booking appointments and accessing remote consultations.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
National Health Service organisations must ensure that all patients have equitable access to care, and that decisions or policies do not unfairly disadvantage people or lead to an increase in inequalities. All NHS organisations are legally obliged to not discriminate.
This means that although we promote digital first services to those who choose to use them, a non-digital solution should be available for those patients who cannot or do not wish to engage digitally to ensure continued, equitable access to care.
These non-digital routes must be available for all services provided by NHS organisations.
We are working to improve access to digital services, outcomes, and experiences for the widest range of people, based on their preferences. Digital health tools should be part of a wider offering that includes face-to-face support with appropriate help for people who struggle to access digital services.
Asked by: Lord Kamall (Conservative - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what assessment they have made of the potential impact of reference pricing for drugs on long-term system capacity and the ability of clinicians to tailor treatments to complex patient profiles within ophthalmology services.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
No specific assessment has been made.
The intention of the reference pricing is to support long term capacity in ophthalmology by enabling trusts to reinvest realised savings directly into local services, including workforce, equipment, and service redesign. Clinical autonomy is maintained, and clinicians will continue to be able to tailor treatments to individual patient needs, including complex cases, where this is clinically indicated.
Asked by: Sarah Bool (Conservative - South Northamptonshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what discussions he has had with the NHS Business Services Authority on extending the duration of Medical Exemption Certificates for those with long-term conditions.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
My Rt Hon. Friend, the Secretary of State for Health and Social Care, has had no such discussions.
Asked by: Ben Spencer (Conservative - Runnymede and Weybridge)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what discussions he has had with Surrey and Borders Partnership NHS Foundation Trust on meeting national targets on Autism and ADHD assessments in children.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
My Rt Hon. Friend, the Secretary of State for Health and Social Care, has regular discussions on a wide range of matters, including with trusts and integrated care boards (ICBs).
The Government has recognised that, nationally, demand for assessments for neurodevelopmental conditions such as autism and attention deficit hyperactivity disorder (ADHD) has grown significantly in recent years and that people are experiencing severe delays for accessing such assessments. The Government’s 10-Year Health Plan will make the National Health Service fit for the future and recognises the need for early intervention and support.
It is the responsibility of ICBs to make available appropriate provision to meet the health and care needs of their local population, including access to neurodevelopmental assessments.
Through the Medium-term planning framework, published 24 October, NHS England has set clear expectations for local ICBs and trusts to improve access, experience, and outcomes for autism and ADHD services over the next three years, focusing on improving quality and productivity.
Asked by: Baroness Maclean of Redditch (Conservative - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what safeguards are in place to prevent the risk of overdiagnosing mental health conditions in children and young people.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government recognises rising demand for children and young people’s mental health services.
Through the Plan for Change and our 10-Year Health Plan, we are transforming the mental health system to strengthen clinical pathways and improve access to early support, while reducing the longest waits for specialist care and tackling regional disparities.
The independent review into mental health conditions, attention deficit hyperactivity disorder, and autism is examining the drivers of rising prevalence and demand, to ensure people receive the right support, at the right time, and in the right place.
More widely, we are accelerating the rollout of mental health support teams in schools and colleges, with national coverage expected by 2029. By this spring, approximately 60% of pupils will have access to early mental health support, up from 44% in spring 2024.